返回 
加入收藏
坤泰胶囊联合雌二醇片/雌二醇地屈孕酮片治疗卵巢储备功能减退的临床观察
x
请在关注微信后，向客服人员索取文件
| 篇名： | 坤泰胶囊联合雌二醇片/雌二醇地屈孕酮片治疗卵巢储备功能减退的临床观察 |
| TITLE： | Clinical observation of Kuntai capsule combined with Estradiol tablets/Estradiol dydrogesterone tablets in the treatment of diminished ovarian reserve |
| 摘要： | 目的 观察坤泰胶囊联合雌二醇片/雌二醇地屈孕酮片治疗卵巢储备功能减退（DOR）的临床疗效、安全性、复发情况及对患者卵巢储备功能、性激素和淋巴细胞亚群的影响。方法回顾性分析南阳市第一人民医院165例DOR患者的临床资料，将其中80例采用雌二醇片/雌二醇地屈孕酮片（按说明书用药顺序每天1片）者纳入对照组，85例在对照组基础上联用坤泰胶囊（每次2.0g，每天3次）者纳入观察组，两组疗程均为3个月。比较两组患者的临床疗效、不良反应发生率、复发率以及治疗前后的中医证候积分、卵巢储备功能指标[抗米勒管激素（AMH）、抑制素B（INHB）、窦卵泡计数（AFC）、子宫内膜厚度及卵巢体积]、性激素[促卵泡激素（FSH）、黄体生成素（LH）和雌二醇（E2）]和T淋巴细胞亚群指标（CD3+、CD4+、CD8+、CD4+/CD8+）情况。结果观察组患者的愈显率显著高于对照组（82.35%vs.65.00%，P＜0.05）。与治疗前比较，两组患者治疗后的中医证候积分、FSH和LH水平、CD3+、CD8+均显著降低，AMH、INHB、E2水平和CD4+、CD4+/CD8+、AFC、子宫内膜厚度、卵巢体积均显著升高或增加（P＜0.05），且观察组上述指标的改善程度均显著优于对照组（P＜0.05）。两组患者的不良反应总发生率无明显差异（P＞0.05）。观察组患者治疗后6个月内的复发率显著低于对照组（5.88%vs.21.25%，P＜0.05）。结论坤泰胶囊联合雌二醇片/雌二醇地屈孕酮片治疗DOR的疗效显著，可改善患者卵巢储备功能，调节其性激素和T淋巴细胞亚群水平，减少复发，且安全性较高。 |
| ABSTRACT： | OBJECTIVE To observe the clinical efficacy， safety and recurrence of Kuntai capsules combined with Estradiol tablets/Estradiol dydrogesterone tablets in the treatment of diminished ovarian reserve （DOR） as well as their effects on ovarian reserve function， sex hormones， and lymphocyte subsets. METHODS A retrospective analysis was conducted on the clinical data of 165 DOR patients in Nanyang First People’s Hospital. Among them， 80 patients who received Estradiol tablets/Estradiol dydrogesterone tablets （take one tablet per day according to the medication sequence on the instruction） were included in the control group， while 85 patients who additionally took Kuntai capsules （2.0 g per dose， three times daily） were included in the observation group. The treatment duration for both groups was three months. Clinical efficacy， the incidence of adverse drug reaction （ADR）， recurrence rate， and changes in Traditional Chinese Medicine （TCM） syndrome scores， ovarian reserve function indicators [anti-Müllerian hormone （AMH）， inhibin B （INHB）， antral follicle count （AFC）， endometrial thickness， and ovarian volume]， sex hormones [follicle-stimulating hormone （FSH）， luteinizing hormone （LH）， and estradiol （E2）]， and T lymphocyte subsets （CD3 +， CD4 +， CD8 +， and CD4 +/CD8 +） were compared before and after treatment. RESULTS The cure and significant improvement rate in the observation group was significantly higher than in the control group （82.35% vs. 65.00%， P＜0.05）. Compared to baseline levels， both groups showed significant reductions in TCM syndrome scores， FSH， LH， CD3+ and CD8+ levels after treatment， while AMH， INHB， E2， CD4 +， CD4 +/CD8 +， AFC， endometrial thickness， and ovarian volume significantly increased （P＜0.05）. The degree of improvement in these indicators was significantly greater in the observation group than in the control group （P＜0.05）. There was no significant difference in the total incidence of ADR between the two groups（P＞ 0.05）. However， the recurrence rate within six months post-treatment was significantly lower in the observation group compared to the control group （5.88% vs. 21.25%， P＜0.05）. CONCLUSIONS Kuntai capsules combined with Estradiol tablets/ Estradiol dydrogesterone tablets have a significant therapeutic effect on DOR， which can improve ovarian reserve function of the patient， regulate sex hormone levels and T lymphocyte subsets， and reduce recurrence rates， with a high safety profile. |
| 期刊： | 2025年第36卷第05期 |
| 作者： | 王秀萍；乔献伟；徐冰 |
| AUTHORS： | WANG Xiuping，QIAO Xianwei，XU Bing |
| 关键字： | 坤泰胶囊；卵巢储备功能减退；雌二醇；地屈孕酮；卵巢储备；淋巴细胞；性激素 |
| KEYWORDS： | Kuntai capsules； diminished ovarian reserve； estradiol； dydrogesterone； ovarian reserve； lymphocytes； sex |
| 阅读数： | 6 次 |
| 本月下载数： | 0 次 |
* 注：未经本站明确许可，任何网站不得非法盗链资源下载连接及抄袭本站原创内容资源!在此感谢您的支持与合作！
